What do systematic reviews say?

First‐line angiotensin converting enzyme inhibitor vs placebo

First‐line angiotensin converting enzyme inhibitor probably leads to lower total mortality compared with placebo (moderate certainty).

• First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
  RR 0.83 [0.72, 0.95]
  3 studies · 6002 participants
  Moderate